FY2024 EPS Estimates for Vaxcyte Raised by Leerink Partnrs

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Vaxcyte in a report issued on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of ($3.69) per share for the year, up from their prior forecast of ($3.79). The consensus estimate for Vaxcyte's current full-year earnings is ($4.33) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q4 2024 earnings at ($0.91) EPS, FY2025 earnings at ($4.73) EPS, FY2026 earnings at ($5.42) EPS, FY2027 earnings at ($6.13) EPS and FY2028 earnings at ($5.37) EPS.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.27. During the same period last year, the company earned ($0.91) EPS.

Several other equities analysts also recently issued reports on PCVX. Cantor Fitzgerald reiterated an "overweight" rating on shares of Vaxcyte in a research report on Wednesday. BTIG Research boosted their price objective on Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Bank of America boosted their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, September 4th. Leerink Partners boosted their price objective on Vaxcyte from $106.00 to $153.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC reissued a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded up $3.97 during midday trading on Friday, hitting $106.67. 1,014,877 shares of the company's stock were exchanged, compared to its average volume of 840,864. The stock's 50 day moving average price is $111.04 and its 200-day moving average price is $86.92. Vaxcyte has a twelve month low of $46.16 and a twelve month high of $121.06.

Insider Buying and Selling

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company's stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company's stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the company's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $106.80, for a total value of $854,400.00. Following the completion of the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at $21,968,226. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 115,098 shares of company stock valued at $12,394,473 over the last quarter. Corporate insiders own 3.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PCVX. Darwin Global Management Ltd. raised its stake in Vaxcyte by 374.3% during the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company's stock valued at $187,907,000 after purchasing an additional 2,170,845 shares during the period. Vanguard Group Inc. raised its stake in Vaxcyte by 15.2% during the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company's stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the period. Capital Research Global Investors raised its stake in Vaxcyte by 20.4% during the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company's stock valued at $282,839,000 after purchasing an additional 700,414 shares during the period. Janus Henderson Group PLC raised its stake in Vaxcyte by 9.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company's stock valued at $524,117,000 after purchasing an additional 692,492 shares during the period. Finally, Avoro Capital Advisors LLC purchased a new position in shares of Vaxcyte during the 1st quarter valued at $39,278,000. Institutional investors own 96.78% of the company's stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.